Most people with atypical hemolytic uremic syndrome (aHUS) who are stable on Soliris (eculizumab) can stop treatment after…
Articles by Lindsey Shapiro, PhD
Short-term use of Soliris (eculizumab) in India — where the drug was approved just this year for treating two…
An interactive electronic storybook, or e-book, designed to help children with atypical hemolytic uremic syndrome (aHUS) better understand their…
It may be safe for some adults with atypical hemolytic uremic syndrome (aHUS) to discontinue treatment once they’re clinically…
The National Organization for Rare Disorders (NORD) is offering patient assistance programs specifically for people in the U.S. with…
Long-term treatment with Ultomiris (ravulizumab) led to sustained clinical improvements for adults and children with atypical hemolytic uremic…
Treatment with Soliris (eculizumab) helped about half of the children diagnosed with atypical hemolytic uremic syndrome (aHUS) after they…
Blood concentrations of Soliris (eculizumab) needed to fully suppress the immune complement cascade may be higher than previously thought…
Relapses were less likely in people with atypical hemolytic uremic syndrome (aHUS) treated with Soliris (eculizumab) after a…
People with atypical hemolytic uremic syndrome (aHUS) have an immune cell profile distinct from that of healthy people and…